Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897663 · ClinicalTrials.gov registry record
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
A clinical trial of Brain and Central Nervous System Tumors, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 56
- Enrollment target
- 10
- Study locations
NCT00897663: Completed study of Brain and Central Nervous System Tumors, sponsored by Alliance for Clinical Trials in Oncology.
NCT00897663 is a study of Brain and Central Nervous System Tumors that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 56 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (69% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00897663, a study of Brain and Central Nervous System Tumors, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at tissue samples from patients with glioblastoma multiforme to identify biomarkers that may improve the selection of patients for epidermal growth factor receptor inhibitor therapies.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- GENETIC protein expression analysis
- OTHER immunohistochemistry staining method
- OTHER diagnostic laboratory biomarker analysis
Study Locations (10)
Iowa
- Siouxland Hematology-Oncology Associates, LLP - Sioux City
- Mercy Medical Center - Sioux City - Sioux City
- St. Luke's Regional Medical Center - Sioux City
North Dakota
- Medcenter One Hospital Cancer Care Center - Bismarck
- Mid Dakota Clinic, PC - Bismarck
- St. Alexius Medical Center Cancer Center - Bismarck
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Minnesota
- Mayo Clinic Cancer Center - Rochester
South Dakota
- Rapid City Regional Hospital - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-11 |
| Est. Completion | 2018-01 |
What the finished NCT00897663 record still lists
NCT00897663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00897663 lists 10 locations in 6 states (Iowa, North Dakota, Arizona).
Frequently Asked Questions
What is clinical trial NCT00897663 about?
NCT00897663 is a clinical study titled "Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies". RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at tissue samples from pa...
What is the current status of trial NCT00897663?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2006-11. Estimated completion is 2018-01.
What conditions does trial NCT00897663 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00897663?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), protein expression analysis (GENETIC), immunohistochemistry staining method (OTHER), diagnostic laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00897663?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00897663 being conducted?
This trial has 10 study locations across Arizona, Florida, Iowa, Minnesota, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00897663's enrollment target sits among peer trials
56 21st of 45 higher than 24 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia